All News
Super interesting SpA phenotypical type world map. #ACR23 Abs #2195 continues to prove how heterogenous this disease is and the need for additional therapeutic agents for improved patient outcomes. https://t.co/hpKY7usUUb @rheumnow https://t.co/xJ1bx6wOC0
Dr. Rachel Tate ( View Tweet)
A#2427 #ACR23 @RheumNow
PR3+ cell abundance higher in prolif LN, more than membranous. Mostly in tuberulointerstitium
Density of PR3+ higher in glomueruli of prolif LN
Correlates with activity, not chronicity
Urinary PR3 predict renal fxn loss at 3y
@jhrheumatology @andreafava https://t.co/vvC8lgZgWO
Eric Dein ( View Tweet)
APTURA 1 study of tocilizumab biosimilar. Not surprisingly no difference. I'm excited about this product. Hopefully be the end to our tocilizumab supply issues and significant societal savings Abstr#0445 #ACR23 @RheumNow https://t.co/qvP7LCeAkm https://t.co/Zb1FUAlXlz
Richard Conway ( View Tweet)
What drives fate of synovial fibroblast into being a lining fibroblast?
Presti et al., organoid culture approach:
-Beta catenin seems instrumental
-Cadherin 23 is specific & drives compaction
Big implications for elective FLS targeted ttmt!
@RheumNow #ACR23 ABST2426 https://t.co/9R5AhwE9rQ
Aurelie Najm ( View Tweet)
Lung cancer in RA. @NamrataRheum et al. 26,625 RA HR for lung cancer for b/tsDMARDs vs csDMARDS 1.07 (0.91-1.26) Abstr#0453 #ACR23 @RheumNow https://t.co/NLNtyYoaoH https://t.co/tRpt62n62X
Richard Conway ( View Tweet)
Comorbidities, including heightened CV risk, are linked to severe psoriasis. However, understanding subclinical CV disease timing in psoriasis patients remains limited. Dr. Jack Cush at .@RheumNow explains why more research is needed in this area: https://t.co/3KqQavVEbP https://t.co/Xo8SH0RTh9
RWCS RWCSmtg ( View Tweet)
@rheumnow and Dr Kevin Winthrop #ACR23 - watch what they to say about #COVID #vaccines on https://t.co/2zKD625Yn9 https://t.co/9tCOgNLyO7
TheDaoIndex KDAO2011 ( View Tweet)
MANDARA -52wk,ph3 non-inferiority study comparing efficacy & safety of benralizumab & mepolizumab in EGPA receiving SOC
👉Benralizumab was non-inferior to mepolizumab in achieving remission at wks 36 & 48 (2.71%; 95% CI –12.54, 17.96; p=0.7278)
#ACR ABSTL14 @RheumNow #ACRbest https://t.co/S3aa3g5mnN
sheila ( View Tweet)
K-drama!
Korean database noted smokers and ex-smokers had less OA fewer TKR! These were age, comorbidities matched. Unclear what the data is for sex difference or occupation. Other pubs in the past noted similar observations. Abst#1808 @rheumnow #ACR23 @UnaMakris https://t.co/ZkjWoxD8wD
TheDaoIndex KDAO2011 ( View Tweet)
#ACR23 Abstr#2270 What are the causes of discordance btw #SLE patients and physicians pertaining to disease activity? Survey data from Global COVAD: 45% rate of discordance! Could be related to fatigue levels, pain, poor mental being & impaired physical function @RheumNow https://t.co/kVzGRJm2R8
Md Yuzaiful Md Yusof ( View Tweet)
Great research by @andreafava on urinary biomarkers for lupus nephritis A#0850 #ACR23
IL-17 and other biomarkers can predict renal fxn loss - better than proteinuria!
Article on @RheumNow https://t.co/DeiWFKzNxC
Eric Dein ( View Tweet)
Vasculitis patients associated with increased pregnancy risks
Large study of >600 pregnancies in >500 pts
Vasculitis pts higher frequency of spontaneous abortion, elective termination, ectopic and molar pregnancy, preterm delivery
12% pre-eclampsia
@RheumNow #ACR23 Abs#2425 https://t.co/Nqa77nxSFu
Robert B Chao, MD ( View Tweet)
Pregnancy outcome in Vasculitis - Claim database study
A#2425 #ACR23 @RheumNow
665 vasculitis pts, LVV 60, MV 160, SVV 217, variable 250
Incr risk of preterm delivery, particularly medically-ind deliv, esp Small vessel vasc (5x risk med-induced)
Higer risk pre-eclampsia/eclampsia https://t.co/bWMyY5oqNK
Eric Dein ( View Tweet)
Who knew @FDA_Drug_Info presented #ACR23 posters?! I thought they just issue statements if there was information to be shared! Abst#1822 Bari and Toci use during the pandemic for #COVID19 did not show new safety signals. 1 case HBV reactivation with bari @RheumNow https://t.co/zd7TELsV2j
TheDaoIndex KDAO2011 ( View Tweet)
International collaborative has discussed early referrals for PMR - this is what they’re recommending
Better plans to get the right patients into rheumatologists is a big part of helping #MakeRheumForPMR
ABST2395 #ACR23 @RheumNow https://t.co/Kea07IGxhG
David Liew drdavidliew ( View Tweet)
Antifibrotics in RA-ILD @Juge_P_A Discontinuation in 46% (Mainly GI). Improved FVC trajectory - almost stops decline. Abstr#2479 #ACR23 #ACRbest @RheumNow https://t.co/nZW6TVKefL https://t.co/5BX3PhFhOK
Richard Conway ( View Tweet)
Rashes in Rheumatology at #ACR23
Name the rash? @Rheumnow https://t.co/7CNqOESctW
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
#ACR23 Abstr#2334 Can we achieve #SLE DORIS remission with current therapy? Post-hoc analyses of 3 x RCTs + LTE over 4 years showed anifrolumab therapy was associated with more frequent and sustained remission vs PBO during the 4-year period. Good for long-term outcomes @RheumNow https://t.co/eq02yChTZr
Md Yuzaiful Md Yusof ( View Tweet)
Rashes in Rheumatology at #ACR23
Name the rash? @Rheumnow https://t.co/uFjXEOHczZ
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Dysautonomia & joint hypermobility/hEDS - we all know that patients often have both, but what groups of symptoms cluster for patients?
This French study showed three main groups - need to look at treatment strategies for each group individually
#ACR23 ABST1838 @RheumNow https://t.co/UDepsudpXx
David Liew drdavidliew ( View Tweet)